Daily Archives: September 29, 2022
RCT | In patients with Type 1 Diabetes, the use of a “bionic pancreas” reduced HbA1c without increasing hypoglycemia.
29 Sep, 2022 | 13:35h | UTCMulticenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort Study | Determinants of drug-coated balloon failure in patients undergoing femoropopliteal arterial intervention.
29 Sep, 2022 | 13:33h | UTC
Review | Treatment and prevention of heat-related illness.
29 Sep, 2022 | 13:34h | UTCTreatment and Prevention of Heat-Related Illness
Related:
Commentary on Twitter
Climate change is resulting in higher temperatures and increased risks of mild to life-threatening heat illnesses. Risk can be reduced by counseling susceptible persons about risk-reduction strategies. #GlobalGoals https://t.co/RpRRT2Y7Bj pic.twitter.com/JwvDgHaY1l
— NEJM (@NEJM) September 28, 2022
RCT | Abbreviated antiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk.
29 Sep, 2022 | 13:32h | UTC
WGO Guideline—Endoscope disinfection update.
29 Sep, 2022 | 13:31h | UTCWGO Guideline—Endoscope Disinfection Update – Journal of Clinical Gastroenterology
European Crohn’s and Colitis Guidelines on sexuality, fertility, pregnancy, and lactation.
29 Sep, 2022 | 13:30h | UTC
RCT | Effect of Dimethyl Fumarate vs. Interferon Beta-1a in patients with pediatric-onset multiple sclerosis.
29 Sep, 2022 | 13:29h | UTCInvited Commentary: Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial – JAMA Network Open
See also: Visual Abstract
Viewpoint | Using behavioral economics to decrease operating room costs and promote better surgeon accountability.
29 Sep, 2022 | 13:28h | UTCUsing Behavioral Economics to Decrease Operating Room Costs and Promote Better Surgeon Accountability – JAMA Surgery (free for a limited period)
Temporal association between invasive procedures and infective endocarditis.
29 Sep, 2022 | 13:26h | UTCTemporal association between invasive procedures and infective endocarditis – Heart
Perspective | Same-day discharge after minimally invasive colectomy.
29 Sep, 2022 | 13:27h | UTCSame-Day Discharge After Minimally Invasive Colectomy – JAMA Surgery (free for a limited period)
How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?
29 Sep, 2022 | 13:26h | UTC
Commentary on Twitter
How applicable is the single-dose liposomal amphotericin B (AMBITION regimen) for HIV-associated cryptococcal meningitis to high-income settings?
Very, argue leaders of the @ambitioncm2020 trial in @CIDJournal https://t.co/eUlWG0t1Xv pic.twitter.com/8JGBU1oWeO
— Ilan Schwartz MD PhD (@GermHunterMD) September 27, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
Phase 1 study | GPRC5D-Targeted CAR T Cells for patients with heavily pretreated Multiple Myeloma.
29 Sep, 2022 | 13:25h | UTCGPRC5D-Targeted CAR T Cells for Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
M-A | Carbon dioxide laser vs. vaginal estrogen for genitourinary syndrome of menopause.
29 Sep, 2022 | 13:24h | UTC
Commentary on Twitter
Vaginal laser and vaginal estrogen therapy showed similar improvement in genitourinary symptoms in this systematic review and meta-analysis of RCTs. #Research https://t.co/PpAf77CqKS
— JAMA Network Open (@JAMANetworkOpen) September 21, 2022
RCT | ShangRing vs. Mogen clamp for early infant male circumcision in eastern sub-Saharan Africa.
29 Sep, 2022 | 13:23h | UTCInvited Commentary: Can the ShangRing bring us closer to endorsing early infant male circumcision in sub-Saharan Africa? – The Lancet Global Health
RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.
29 Sep, 2022 | 13:22h | UTCPembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post
Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor
Commentary on Twitter
New Research in @TheLancetOncol—Pembrolizumab improves disease-free survival vs placebo in completely resected, PD-L1-unselected, stage IB–IIIA #NSCLC
From Prof Mary O’Brien & colleagues https://t.co/Azqb8WTOwp pic.twitter.com/141bhAPtg5
— The Lancet Respiratory Medicine (@LancetRespirMed) September 13, 2022
RCT | Immunogenicity and safety of one-dose human papillomavirus vaccine vs. two or three doses.
29 Sep, 2022 | 13:21h | UTCInvited Commentary: HPV vaccines: when one plus one equals three – The Lancet Global Health
Related:
RCT: Single-dose HPV vaccination found effective among young African women.
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
Opinion: A Single-dose HPV Vaccine Would Have a Big Impact on Cancer Prevention
Another Observational Study Suggests One Dose of HPV Vaccine may be Enough
Another Study Suggesting One Dose of HPV Vaccine may be Effective for Prevention of Cervical Cancer
Large Observational Study Suggests One Dose of HPV Vaccine May Be as Effective as Three